公开(公告)号：US20090068276A1

公开(公告)日：2009-03-12

申请号：US12154415

申请日：2008-05-22

Applicant: Mark Jonathan Main ,  Martin James Oliver ,  Timothy Wright

Inventor： Mark Jonathan Main ,  Martin James Oliver ,  Timothy Wright

IPC: A61K9/14 ,  A61K31/55 ,  A61P11/00

CPC classification number: A61K31/55 ,  A61K9/0075 ,  A61K9/1617

Abstract: The present invention relates to new pharmaceutical formulations comprising pharmaceutically active agents which can induce one or more involuntary coughs in a patient when administered as conventional formulations and/or via conventional routes. Formulations are provided comprising a cough-inducing pharmaceutically active agent, wherein the formulation may be administered by pulmonary inhalation without inducing a cough. Alternatively, formulations are provided for administering the cough-inducing active agent via an alternative route.

Abstract translation: 本发明涉及包含药物活性剂的新型药物制剂，当以常规制剂和/或通过常规途径给药时，其可以诱导患者中的一种或多种非自愿咳嗽。 提供了包含咳嗽诱导药物活性剂的制剂，其中所述制剂可以通过肺吸入而不引起咳嗽而施用。 或者，提供用于通过替代途径施用咳嗽诱导活性剂的制剂。

公开(公告)号：US20110077272A1

公开(公告)日：2011-03-31

申请号：US12865340

申请日：2009-02-02

Applicant: Mark Jonathan Main

Inventor： Mark Jonathan Main

IPC: A61K31/454 ,  C07D209/16 ,  A61K31/404 ,  C07D403/10 ,  A61K31/4196 ,  C07D401/04 ,  C07D413/10 ,  A61K31/422 ,  C07D403/06 ,  C07D209/58 ,  A61K31/403 ,  A61P25/06

CPC classification number: A61K31/4045 ,  A61K9/0073 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/454 ,  A61K47/26

Abstract: A pharmaceutical composition includes triptans, such as sumatriptan, and may be used in therapy. The composition may be administered via the inhaled route.

Abstract translation: 药物组合物包括曲坦类，如舒马曲坦，可用于治疗。 组合物可以经由吸入途径施用。

公开(公告)号：US20100288276A1

公开(公告)日：2010-11-18

申请号：US12740323

申请日：2008-10-31

Applicant: David Ganderton ,  Mark Jonathan Main ,  Frazer Giles Morgan

Inventor： David Ganderton ,  Mark Jonathan Main ,  Frazer Giles Morgan

IPC: A61K31/4375 ,  A61P25/16 ,  A61P25/00 ,  A61M15/00 ,  A61M16/10

CPC classification number: A61K9/1688 ,  A61K9/0075 ,  A61K9/008 ,  A61K9/145 ,  A61K31/485

Abstract: The present invention relates to improved treatment of diseases and disorders of the central nervous system by administration of apomorphine. In particular, the administration is via pulmonary inhalation. The invention provides the means for improving the treatment of a number of conditions, including Parkinson's Disease.

Abstract translation: 本发明涉及通过给予阿朴吗啡来改善中枢神经系统疾病和病症的治疗。 特别地，给药是通过肺部吸入。 本发明提供了改善治疗包括帕金森病在内的许多病症的方法。

公开(公告)号：US20130287854A1

公开(公告)日：2013-10-31

申请号：US13885531

申请日：2011-11-15

Applicant: Frazer Giles Morgan ,  Mark Jonathan Main

Inventor： Frazer Giles Morgan ,  Mark Jonathan Main

IPC: A61K9/00 ,  A61K31/277 ,  A61K45/06 ,  A61K31/473 ,  A61K31/198

CPC classification number: A61K9/0075 ,  A61K31/195 ,  A61K31/198 ,  A61K31/275 ,  A61K31/277 ,  A61K31/4045 ,  A61K31/428 ,  A61K31/473 ,  A61K31/48 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

Abstract: According to the invention there is provided a method of treating and/or preventing the symptoms of Parkinson's disease comprising delivering apomorphine, optionally in combination with levodopa and/or a dopamine agonist that is not apomorphine, wherein apomorphine is administered by inhalation.

Abstract translation: 根据本发明，提供了治疗和/或预防帕金森病症状的方法，包括递送阿扑吗啡，任选与左旋多巴和/或不是阿扑吗啡的多巴胺激动剂组合，其中阿扑吗啡通过吸入给药。